Grey Wolf reels in $50M to expand into autoimmune diseases

Kyle LaHucik

Senior Reporter

Grey Wolf Therapeutics raised another $50 million, which is set to extend its runway through 2026 and fund another clinical trial, this time in autoimmune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Grey Wolf reels in $50M to expand into autoimmune diseases

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

Gilead cancer drug magrolimab showed worrying trends around death

Nurix’s protein degrader overcomes resistance to BTK mutations in small leukemia study

Rare pediatric disease vouchers face uncertain future after September

De-risking the patient journey in cell therapies: Six key considerations

Grey Wolf reels in $50M to ex­pand in­to au­toim­mune dis­eases

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Nurix’s pro­tein de­grad­er over­comes re­sis­tance to BTK mu­ta­tions in small leukemia study

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

Grey Wolf reels in $50M to expand into autoimmune diseases

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

Gilead cancer drug magrolimab showed worrying trends around death

Nurix’s protein degrader overcomes resistance to BTK mutations in small leukemia study

Rare pediatric disease vouchers face uncertain future after September

De-risking the patient journey in cell therapies: Six key considerations